Search

Your search keyword '"Milanesi N"' showing total 79 results
Start Over Author "Milanesi N"
79 results on '"Milanesi N"'

2. The new Italian SIDAPA Baseline Series for patch testing (2023): an update according to the new regulatory pathway for contact allergens

Author

Stingeni, L, Bianchi, L, Caroppo, E, Belloni Fortina, A, Caroppo, F, Corazza, M, Borghi, A, Gallo, R, Trave, I, Ferrucci, S, Beretta, A, Guarneri, F, Martina, E, Napolitano, M, de Lucia, M, Patruno, C, Bennardo, L, Romita, P, Foti, C, Tramontana, M, Marietti, R, Argenziano, G, Hansel, K, Abategiovanni, L, Albertazzi, D, Ali Biglu Marash, S, Amendolagine, G, Angelini, G, Annunziata, A, Assalve, D, Ayala, F, Babino, G, Barruscotti, S, Battista, T, Berta, M, Biondi, F, Boccaletti, V, Bonamonte, D, Bruni, F, Buffon, R, Caccavale, S, Calabrese, L, Calzavara Pinton, P, Camela, E, Carugno, A, Casciola, G, Cecchini, E, Cristaudo, A, D'Agostino, M, Damiani, G, Danese, P, Dattola, A, de Salvo, V, Errichetti, E, Esposito, G, Esposito, M, Fantini, C, Fontana, E, Fornaro, L, Frasin, L, Galeotti, T, Gasparini, G, Genco, L, Gravante, M, Guastaferro, D, Guerrasio, G, Guerriero, L, Lauro, W, Lucagnano, G, Malatesta, N, Mandel, V, Marano, L, Marino, V, Martora, F, Menna, L, Miano, C, Miccio, L, Michelerio, A, Milanesi, N, Monfrecola, G, Motolese, A, Nocerino, M, Noto, M, Ornielli, M, Pacifico, A, Papini, M, Pasolini, G, Penchini, L, Perazzolli, G, Peserico, A, Piccolo, V, Pigatto, P, Potestio, L, Pugliese, A, Recalcati, S, Rivetti, N, Rossi, M, Russo, F, Russo, T, Schena, D, Sensini, C, Tesauri, D, Tomassini, G, Ventura, V, Venturini, M, Vezzoli, P, Vincenzi, C, Stingeni L., Bianchi L., Caroppo E. S., Belloni Fortina A., Caroppo F., Corazza M., Borghi A., Gallo R., Trave I., Ferrucci S. M., Beretta A., Guarneri F., Martina E., Napolitano M., de Lucia M., Patruno C., Bennardo L., Romita P., Foti C., Tramontana M., Marietti R., Argenziano G., Hansel K., Abategiovanni L., Albertazzi D., Ali Biglu Marash S., Amendolagine G., Angelini G., Annunziata A., Assalve D., Ayala F., Babino G., Barruscotti S., Battista T., Berta M., Biondi F., Boccaletti V., Bonamonte D., Bruni F., Buffon R., Caccavale S., Calabrese L., Calzavara Pinton P., Camela E., Carugno A., Casciola G., Cecchini E., Cristaudo A., D'Agostino M., Damiani G., Danese P., Dattola A., de Salvo V., Errichetti E., Esposito G., Esposito M., Fantini C., Fontana E., Fornaro L., Frasin L. A., Galeotti T., Gasparini G., Genco L., Gravante M., Guastaferro D., Guerrasio G., Guerriero L., Lauro W., Lucagnano G., Malatesta N., Mandel V. D., Marano L., Marino V., Martora F., Menna L., Miano C., Miccio L., Michelerio A., Milanesi N., Monfrecola G., Motolese A., Nocerino M., Noto M., Ornielli M., Pacifico A., Papini M., Pasolini G., Penchini L., Perazzolli G., Peserico A., Piccolo V., Pigatto P., Potestio L., Pugliese A., Recalcati S., Rivetti N., Rossi M., Russo F., Russo T., Schena D., Sensini C., Tesauri D., Tomassini G. M., Ventura V., Venturini M., Vezzoli P., Vincenzi C., Stingeni, L, Bianchi, L, Caroppo, E, Belloni Fortina, A, Caroppo, F, Corazza, M, Borghi, A, Gallo, R, Trave, I, Ferrucci, S, Beretta, A, Guarneri, F, Martina, E, Napolitano, M, de Lucia, M, Patruno, C, Bennardo, L, Romita, P, Foti, C, Tramontana, M, Marietti, R, Argenziano, G, Hansel, K, Abategiovanni, L, Albertazzi, D, Ali Biglu Marash, S, Amendolagine, G, Angelini, G, Annunziata, A, Assalve, D, Ayala, F, Babino, G, Barruscotti, S, Battista, T, Berta, M, Biondi, F, Boccaletti, V, Bonamonte, D, Bruni, F, Buffon, R, Caccavale, S, Calabrese, L, Calzavara Pinton, P, Camela, E, Carugno, A, Casciola, G, Cecchini, E, Cristaudo, A, D'Agostino, M, Damiani, G, Danese, P, Dattola, A, de Salvo, V, Errichetti, E, Esposito, G, Esposito, M, Fantini, C, Fontana, E, Fornaro, L, Frasin, L, Galeotti, T, Gasparini, G, Genco, L, Gravante, M, Guastaferro, D, Guerrasio, G, Guerriero, L, Lauro, W, Lucagnano, G, Malatesta, N, Mandel, V, Marano, L, Marino, V, Martora, F, Menna, L, Miano, C, Miccio, L, Michelerio, A, Milanesi, N, Monfrecola, G, Motolese, A, Nocerino, M, Noto, M, Ornielli, M, Pacifico, A, Papini, M, Pasolini, G, Penchini, L, Perazzolli, G, Peserico, A, Piccolo, V, Pigatto, P, Potestio, L, Pugliese, A, Recalcati, S, Rivetti, N, Rossi, M, Russo, F, Russo, T, Schena, D, Sensini, C, Tesauri, D, Tomassini, G, Ventura, V, Venturini, M, Vezzoli, P, Vincenzi, C, Stingeni L., Bianchi L., Caroppo E. S., Belloni Fortina A., Caroppo F., Corazza M., Borghi A., Gallo R., Trave I., Ferrucci S. M., Beretta A., Guarneri F., Martina E., Napolitano M., de Lucia M., Patruno C., Bennardo L., Romita P., Foti C., Tramontana M., Marietti R., Argenziano G., Hansel K., Abategiovanni L., Albertazzi D., Ali Biglu Marash S., Amendolagine G., Angelini G., Annunziata A., Assalve D., Ayala F., Babino G., Barruscotti S., Battista T., Berta M., Biondi F., Boccaletti V., Bonamonte D., Bruni F., Buffon R., Caccavale S., Calabrese L., Calzavara Pinton P., Camela E., Carugno A., Casciola G., Cecchini E., Cristaudo A., D'Agostino M., Damiani G., Danese P., Dattola A., de Salvo V., Errichetti E., Esposito G., Esposito M., Fantini C., Fontana E., Fornaro L., Frasin L. A., Galeotti T., Gasparini G., Genco L., Gravante M., Guastaferro D., Guerrasio G., Guerriero L., Lauro W., Lucagnano G., Malatesta N., Mandel V. D., Marano L., Marino V., Martora F., Menna L., Miano C., Miccio L., Michelerio A., Milanesi N., Monfrecola G., Motolese A., Nocerino M., Noto M., Ornielli M., Pacifico A., Papini M., Pasolini G., Penchini L., Perazzolli G., Peserico A., Piccolo V., Pigatto P., Potestio L., Pugliese A., Recalcati S., Rivetti N., Rossi M., Russo F., Russo T., Schena D., Sensini C., Tesauri D., Tomassini G. M., Ventura V., Venturini M., Vezzoli P., and Vincenzi C. more...

Abstract

Allergic contact dermatitis (ACD) is a common inflammatory skin disease caused by delayed hypersensitivity to chemical and biotic contact allergens. ACD significantly affects the patients' quality of life negatively impacting both occupational and non-occupational settings. Patch testing is the gold standard diagnostic in vivo test to precise the ACD etiology and to correctly perform prevention. According to the Italian Medicines Agency (AIFA) legislative decree no. 178 of 29th May 1991, allergens are defined as medicines and therefore they are subject to strict regulation. In 2017, AIFA (decree no. 2130/2017) started a procedure to regulate contact allergens on the Italian market and actually the contact allergens temporarily authorized are reported in AIFA decree no. 98/2022, valid until November 2023. The availability on the market of contact allergens to diagnose ACD and continuous updating on the basis of new epidemiological trends are mandatory, jointly with the continuous update of the baseline and integrative series for patch testing. For this reason, the scientific community represented in Italy by the Skin Allergies Study Group of SIDeMaST (Italian Society of Dermatology and Venereology) and SIDAPA (Italian Society of Allergological, Occupational and Environmental Dermatology) are constantly working, in close relationship with the European scientific communities with large expertise in this important sector of the modern Dermatology. Herein, we report the setting up of regulatory legislation by AIFA and the new Italian Adult Baseline Series for patch testing. more...

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results

3. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., Peris, K., Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., and Peris, K. more...

Published
2022

4. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis

Author

Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), Fargnoli M. C., Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), and Fargnoli M. C. more...

Abstract

na

Published
2023

5. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience

Author

Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, K., Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Fargnoli, M. C., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, A., Tramontana, M., Hansel, K., Bini, V., Buligan, C., Caroppo, F., Dal Bello, G., Dastoli, S., Di Brizzi, E. V., De Felici Del Giudice, M. B., Diluvio, L., Esposito, M., Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Peccerillo, F., Pluchino, F., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Stingeni, L, Bianchi, L, Antonelli, E, Caroppo, E S, Ferrucci, S M, Ortoncelli, M, Fabbrocini, G, Nettis, E, Schena, D, Napolitano, M, Gola, M, Bonzano, L, Rossi, M, Belloni Fortina, A, Balato, A, Peris, K, Foti, C, Guarneri, F, Romanelli, M, Patruno, C, Savoia, P, Fargnoli, M C, Russo, F, Errichetti, E, Bianchelli, T, Pellacani, G, Feliciani, C, Offidani, A, Corazza, M, Micali, G, Milanesi, N, Malara, G, Chiricozzi, A, Tramontana, M, and Hansel, K more...

Subjects
SARS-CoV-2, Pruritus, Eczema, COVID-19, Dermatitis, Dermatology, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Atopic, Antibodies, COVID-19 Drug Treatment, Dermatitis, Atopic, Treatment Outcome, Settore MED/35, Infectious Diseases, Double-Blind Method, Monoclonal, Humans, Prospective Studies, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Pandemics, Humanized
Abstract

Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to more...

Published
2022

6. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., Piras V., Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., and Piras V. more...

Abstract

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients. more...

Published
2021

7. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience

Author

Stingeni, L, Bianchi, L, Antonelli, E, Caroppo, E S, Ferrucci, S M, Ortoncelli, M, Fabbrocini, G, Nettis, E, Schena, D, Napolitano, M, Gola, M, Bonzano, L, Rossi, M, Belloni Fortina, A, Balato, A, Peris, Ketty, Foti, C, Guarneri, F, Romanelli, M, Patruno, C, Savoia, P, Fargnoli, M C, Russo, F, Errichetti, E, Bianchelli, T, Pellacani, G, Feliciani, C, Offidani, A, Corazza, M, Micali, G, Milanesi, N, Malara, G, Chiricozzi, Andrea, Tramontana, M, Hansel, K, Peris, K (ORCID:0000-0002-5237-0463), Chiricozzi, A (ORCID:0000-0002-6739-0387), Stingeni, L, Bianchi, L, Antonelli, E, Caroppo, E S, Ferrucci, S M, Ortoncelli, M, Fabbrocini, G, Nettis, E, Schena, D, Napolitano, M, Gola, M, Bonzano, L, Rossi, M, Belloni Fortina, A, Balato, A, Peris, Ketty, Foti, C, Guarneri, F, Romanelli, M, Patruno, C, Savoia, P, Fargnoli, M C, Russo, F, Errichetti, E, Bianchelli, T, Pellacani, G, Feliciani, C, Offidani, A, Corazza, M, Micali, G, Milanesi, N, Malara, G, Chiricozzi, Andrea, Tramontana, M, Hansel, K, Peris, K (ORCID:0000-0002-5237-0463), and Chiricozzi, A (ORCID:0000-0002-6739-0387) more...

Abstract

Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. Methods Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. Results One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. Conclusions Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era. more...

Published
2022

8. Contact allergy to hydrocortisone 21-acetate in Italy: A SIDAPA multicenter study

Author

Stingeni, L., Marietti, R., Bianchi, L., Ferrucci, S. M., Foti, C., Patruno, C., Napolitano, M., Gallo, R., Corazza, M., Schena, D., Tramontana, M., Hansel, K., Bruni, F., Faraci, A. G., Guarneri, F., Martina, E., Milanesi, N., Musumeci, M. L., Pigatto, P., Piras, V., and Romita, P. more...

Subjects
SIDAPA baseline series, Adult, Male, medicine.medical_specialty, Hydrocortisone, Anti-Inflammatory Agents, Dermatology, corticosteroids, Hydrocortisone 21-acetate, medicine, Prevalence, Immunology and Allergy, Humans, Aged, business.industry, Patch test, Middle Aged, Patch Tests, hydrocortisone 21-acetate, Multicenter study, Italy, Contact allergy, Dermatitis, Allergic Contact, Female, business, patch test
Published
2021

10. Italian Guidelines in patch testing - Adapted from the European Society of Contact Dermatitis (ESCD)

Author

Stingeni, L, Bianchi, L, Hansel, K, Corazza, M, Gallo, R, Guarneri, F, Patruno, C, Rigano, L, Romita, P, Pigattoatt, P, Calzavara-Pintoton, P, Agostinelli, S, Albertazzi, D, Angelini, G, Angerosa, F, Arigliano, P, Assalve, D, Ayala, F, Bellonifortina, A, Berta, M, Biale, C, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Brambilla, L, Bressan, M, Bruno, A, Caccavale, S, Calogiuri, G, Cannavò, S, Carugno, A, Cataldi, I, Chiarelli, G, Chiesa, A, Cirla, A, Cossutta, M, Cova, L, Cristaudo, A, Dalcan-Ton, M, Damiani, G, Danese, P, Desalvo, V, Fantini, C, Ferrucci, S, Flori, M, Fontana, E, Foti, C, Francalanci, S, Frasin, L, Gola, M, Gravante, M, Guastaferro, D, Ingordo, V, Lauriola, M, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Magrini, L, Marone, G, Martina, E, Mascagni, P, Matteinichiari, M, Meligeni, L, Melino, M, Milanesi, N, Molinu, A, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, M, Napolitano, M, Nasca, M, Paganini, P, Papini, M, Pasolini, G, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, P, Rebora, A, Recchia, G, Riva, F, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spano, G, Stinchi, C, Taddei, L, Tasin, L, Tramontana, M, Valsecchi, R, Vascellaro, A, Venturini, M, Stingeni, L., Bianchi, L., Hansel, K., Corazza, M., Gallo, R., Guarneri, F., Patruno, C., Rigano, L., Romita, P., Pigattoatt, P. D., Calzavara-Pintoton, P., Agostinelli, S., Albertazzi, D., Angelini, G., Angerosa, F., Arigliano, P. L., Assalve, D., Ayala, F., Bellonifortina, A., Berta, M., Biale, C., Biasini, I., Boccaletti, V., Bonamonte, D., Borghi, A., Brambilla, L., Bressan, M., Bruno, A., Caccavale, S., Calogiuri, G., Cannavò, S. P., Carugno, A., Cataldi, I., Chiarelli, G., Chiesa, A., Cirla, A. M., Cossutta, M., Cova, L. M., Cristaudo, A., Dalcan-Ton, M., Damiani, G., Danese, P., Desalvo, V., Fantini, C., Ferrucci, S. M., Flori, M. L., Fontana, E., Foti, C., Francalanci, S., Frasin, L. A., Gola, M., Gravante, M., Guastaferro, D., Ingordo, V., Lauriola, M. M., Leghissa, P., Lisi, P., Lombardi, P., Lorenzini, M., Magrini, L., Marone, G., Martina, E., Mascagni, P., Matteinichiari, M., Meligeni, L., Melino, M., Milanesi, N., Molinu, A. A., Monfrecola, G., Morelli, P., Motolese, A., Musumeci, M. L., Napolitano, M., Nasca, M. R., Paganini, P., Papini, M., Pasolini, G., Peroni, A., Peserico, A., Piras, V., Pugliese, A., Raponi, F., Raviolo, P. D., Rebora, A., Recchia, G. P., Riva, F., Rossi, M., Ruggieri, M., Saggiorato, F., Sartorelli, P., Schena, D., Schettino, A., Spano, G., Stinchi, C., Taddei, L., Tasin, L., Tramontana, M., Valsecchi, R. H., Vascellaro, A., Venturini, M., Stingeni, L, Bianchi, L, Hansel, K, Corazza, M, Gallo, R, Guarneri, F, Patruno, C, Rigano, L, Romita, P, Pigattoatt, P, Calzavara-Pintoton, P, Agostinelli, S, Albertazzi, D, Angelini, G, Angerosa, F, Arigliano, P, Assalve, D, Ayala, F, Bellonifortina, A, Berta, M, Biale, C, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Brambilla, L, Bressan, M, Bruno, A, Caccavale, S, Calogiuri, G, Cannavò, S, Carugno, A, Cataldi, I, Chiarelli, G, Chiesa, A, Cirla, A, Cossutta, M, Cova, L, Cristaudo, A, Dalcan-Ton, M, Damiani, G, Danese, P, Desalvo, V, Fantini, C, Ferrucci, S, Flori, M, Fontana, E, Foti, C, Francalanci, S, Frasin, L, Gola, M, Gravante, M, Guastaferro, D, Ingordo, V, Lauriola, M, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Magrini, L, Marone, G, Martina, E, Mascagni, P, Matteinichiari, M, Meligeni, L, Melino, M, Milanesi, N, Molinu, A, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, M, Napolitano, M, Nasca, M, Paganini, P, Papini, M, Pasolini, G, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, P, Rebora, A, Recchia, G, Riva, F, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spano, G, Stinchi, C, Taddei, L, Tasin, L, Tramontana, M, Valsecchi, R, Vascellaro, A, Venturini, M, Stingeni, L., Bianchi, L., Hansel, K., Corazza, M., Gallo, R., Guarneri, F., Patruno, C., Rigano, L., Romita, P., Pigattoatt, P. D., Calzavara-Pintoton, P., Agostinelli, S., Albertazzi, D., Angelini, G., Angerosa, F., Arigliano, P. L., Assalve, D., Ayala, F., Bellonifortina, A., Berta, M., Biale, C., Biasini, I., Boccaletti, V., Bonamonte, D., Borghi, A., Brambilla, L., Bressan, M., Bruno, A., Caccavale, S., Calogiuri, G., Cannavò, S. P., Carugno, A., Cataldi, I., Chiarelli, G., Chiesa, A., Cirla, A. M., Cossutta, M., Cova, L. M., Cristaudo, A., Dalcan-Ton, M., Damiani, G., Danese, P., Desalvo, V., Fantini, C., Ferrucci, S. M., Flori, M. L., Fontana, E., Foti, C., Francalanci, S., Frasin, L. A., Gola, M., Gravante, M., Guastaferro, D., Ingordo, V., Lauriola, M. M., Leghissa, P., Lisi, P., Lombardi, P., Lorenzini, M., Magrini, L., Marone, G., Martina, E., Mascagni, P., Matteinichiari, M., Meligeni, L., Melino, M., Milanesi, N., Molinu, A. A., Monfrecola, G., Morelli, P., Motolese, A., Musumeci, M. L., Napolitano, M., Nasca, M. R., Paganini, P., Papini, M., Pasolini, G., Peroni, A., Peserico, A., Piras, V., Pugliese, A., Raponi, F., Raviolo, P. D., Rebora, A., Recchia, G. P., Riva, F., Rossi, M., Ruggieri, M., Saggiorato, F., Sartorelli, P., Schena, D., Schettino, A., Spano, G., Stinchi, C., Taddei, L., Tasin, L., Tramontana, M., Valsecchi, R. H., Vascellaro, A., and Venturini, M. more...

Abstract

Patch testing is the standard procedure used to diagnose allergic contact dermatitis. It is an in-vivo test, which reproduces the reaction to a contact allergen. This in-vivo test aims to reproduce the elicitation phase of allergic contact dermatitis and is performed applying allergens under occlusion on the skin under standardized conditions. These guidelines for the best practice in performing patch test have been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Society of Contact Dermatitis (ESCD) and on the basis of the SIDAPA guidelines. more...

Published
2019

11. Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis)

Author

Damiani, G, Calzavara-Pinton, P, Stingeni, L, Hansel, K, Cusano, F, 'Skin Allergy' Group of SIDeMaST, 'ADOI' (Associazione Dermatologi Ospedalieri Italiani), 'SIDAPA' (Società Italiana di Dermatologia Allergologica Professionale, e Ambientale), Agostinelli, D., Albertazzi, D., Angelini, G, Angerosa, F, Arigliano, Pl, Assalve, D, Ayala, F, Barbagallo, T, Belloni-Fortina, A, Berta, M, Biale, C, Bianchi, L, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Bragazzi, Nl, Brambilla, L, Bressan, M, Brunasso, Amg, Bruni, F, Bruni, P, Caccavale, S, Calogiuri, G, Cannavò, Sp, Carugno, A, Cataldi, I, Chiarelli, G, Cirla, Am, Corazza, M, Cossutta, M, Cova, L, Cristaudo, A, Danese, P, Dal Canton, M, De Pità, O, De Salvo, P, Donini, M, Fantini, F, Ferrucci, Sm, Flori, Ml, Fontana, E, Foti, C, Francalci, S, Frasin, La, Gallo, R, Gasparini, G, Gola, M, Gravante, M, Guarnieri, F, Guastaferro, D, Ingordo, V, Lauriola, Mm, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Malara, G, Magrini, L, Marone, G, Martina, E, Mascagni, P, Matteini Chiari, M, Meligeni, L, Melino, M, Miccio, L, Milanesi, N, Molinu, A, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, Ml, Naldi, L, Napolitano, M, Nasca, Mr, Pacifico, A, Paganini, P, Papini, M, Pasolini, G, Patruno, C, Pellegrino, M, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, Pd, Rebora, A, Recchia, Gp, Riva, F, Romita, P, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spanò, G, Stinchi, C, Tasin, L, Tramontana, M, Taddei, L, Valsecchi, Re, Russo, F, Vascellaro, A, Venturini, M, Vincenzi, C, Virgili, A, Pigatto PDM, Zucca M)., Damiani, G, Calzavara-Pinton, P, Stingeni, L, Hansel, K, Cusano, F, Pigatto, P, Agostinelli, D, Albertazzi, D, Angelini, G, Angerosa, F, Arigliano, P, Assalve, D, Ayala, F, Barbagallo, T, Belloni-Fortina, A, Berta, M, Biale, C, Bianchi, L, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Bragazzi, N, Brambilla, L, Bressan, M, Brunasso, A, Bruni, F, Bruni, P, Caccavalle, S, Calogiuri, G, Cannavo, S, Carugno, A, Cataldi, I, Chiarelli, G, Cirla, A, Corazza, M, Cossutta, M, Cova, L, Cristaudo, A, Danese, P, Dal Canton, M, Depita, O, De Salvo, P, Donini, M, Fantini, F, Ferrucci, S, Flori, M, Fontana, E, Foti, C, Francalci, S, Frasin, L, Gallo, R, Gasparini, G, Gola, M, Gravante, M, Guarnieri, F, Guastaferro, D, Ingordo, V, Lauriola, M, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Malara, G, Magrini, L, Marone, G, Martina, E, Mascagni, P, Chiari, M, Meligeni, L, Melino, M, Miccio, L, Milanesi, N, Molinu, A, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, M, Naldi, L, Napolitano, M, Nasca, M, Pacifico, A, Paganini, P, Papini, M, Pasolini, G, Patruno, C, Pellegrino, M, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, P, Rebora, A, Recchia, G, Riva, F, Romita, P, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spano, G, Stinchi, C, Tasin, L, Tramontana, M, Taddei, L, Valsecchi, R, Russo, F, Vascellaro, A, Venturini, M, Vincenzi, C, Virgili, A, Zucca, M, G., Damiani, P., Calzavara-Pinton, L., Stingeni, K., Hansel, F., Cusano, L Arigliano, P, L Bragazzi, N, G Brunasso, A M, Caccavale, S, P Cannavò, S, M Cirla, A, De Pità, O, M Ferrucci, S, L Flori, M, A Frasin, L, M Lauriola, M, Matteini Chiari, M, L Musumeci, M, R Nasca, M, D Raviolo, P, P Recchia, G, Spanò, G, E Valsecchi, R, and P. D. M., Pigatto more...

Subjects
dermatological agents, Cultural context, atopic eczema, Dermatitis, azatioprin, 030207 dermatology & venereal diseases, 0302 clinical medicine, cclosporin, topical, atopic dermatitis, cyclosporin, dupilumab, methotrexate, phototherapy, topicals, Adult, Biological Products, Child, Dermatitis, Atopic, Dermatologic Agents, Dermatology, Humans, Italy, Practice Guidelines as Topic, General Medicine, Atopic dermatitis, Dupilumab, 030220 oncology & carcinogenesis, Revolutionary change, Biological Product, Human, atopic dermatiti, medicine.medical_specialty, atopic dermatitis, atopic eczema, azatioprin, cclosporin, dupilumab, methotrexate, phototherapy, topicals, adult, biological products, child, dermatological agents, Dermatologic Agent, Socio-culturale, Context (language use), Atopic, 03 medical and health sciences, Therapeutic approach, Settore MED/35, Eczema atopic dermatitis, medicine, business.industry, medicine.disease, Family medicine, Good clinical practice, business
Abstract

Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. Availability in daily practice of the last version of international AD guidelines, taking peculiarities of the country into account, can contribute to good clinical practice in Italy. To adapt European Dermatology Forum (EDF) guidelines for AD to the Italian medical–legal context, the EDF guidelines were assessed independently by two independent Italian renowned experts in the field and further integrated with articles published and systematically reviewed before May 2019. The first draft was collegially corrected and updated by the members of the SIDEMAST, ADOI, and SIDAPA. Recommendation levels (A; B; C; D) were graded based on the evidence levels (1–4). The adapted guidelines presented here focus on topical and systemic therapies in AD patients, both children and adults. As opposed to previous Italian guidelines, they include indications about biologics. New relevant evidence available from very recent literature and peculiarities of the Italian medical and legal context have been integrated in the revision process. If compared to general guidelines for AD not adapted to a specific national and cultural context, a revision for specific Italian needs is now available: It comprises the option of implementing the new biologic treatments and is likely to provide an important contribution to the improvement of clinical practice in Italy. Cooperation between patients, dermatologists, allergologists, and pediatricians remains mandatory in AD management. The authors of the present revision recommend an update of the Italian guidelines to be performed at least every second year. more...

Published
2019

12. Italian Guidelines in Patch Testing - adapted from the European Society of Contact Dermatitis (ESCD)

Author

Stingeni, Luca, Bianchi, Leonardo, Hansel, Katharina, Corazza, Monica, Gallo, Rosella, Guarneri, Fabrizio, Patruno, Cataldo, Rigano, Luigi, Romita, Paolo, Pigatto, Paolo D, Calzavara-Pinton, Piergiacomo, Agostinelli, D, Albertazzi, D, Angelini, G, Angerosa, F, Arigliano, Pl, Assalve, D, Ayala, F, Belloni, Fortina, A, Berta, M, Biale, C, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Brambilla, L, Bressan, M, Bruno, A, Caccavale, S, Calogiuri, G, Cannavò, Sp, Carugno, A, Cataldi, I, Chiarelli, G, Chiesa, A, Cirla, Am, Cossutta, M, Cova, Lm, Cristaudo, A, Dal Canton, M, Damiani, G, Danese, P, De Salvo, V, Fantini, C, Ferrucci, Sm, Flori, Ml, Fontana, E, Foti, C, Francalanci, S, Frasin, La, Gola, M, Gravante, M, Guastaferro, D, Ingordo, V, Lauriola, Mm, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Magrini, L, Marone, G, Martina, E, Mascagni, P, Matteini, Chiari, M, Meligeni, L, Melino, M, Milanesi, N, Molinu, Aa, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, Ml, Napolitano, M, Nasca, Mr, Paganini, P, Papini, M, Pasolini, G, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, Pd, Rebora, A, Recchia, Gp, Riva, F, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spano, G, Stinchi, C, Taddei, L, Tasin, L, Tramontana, M, Valsecchi, Rh, Vascellaro, A, Venturini, M, Vincenzi, C, Virgili, A, Zucca, M, Stingeni, L, Bianchi, L, Hansel, K, Corazza, M, Gallo, R, Guarneri, F, Patruno, C, Rigano, L, Romita, P, Pigattoatt, P, Calzavara-Pintoton, P, Agostinelli, S, Albertazzi, D, Angelini, G, Angerosa, F, Arigliano, P, Assalve, D, Ayala, F, Bellonifortina, A, Berta, M, Biale, C, Biasini, I, Boccaletti, V, Bonamonte, D, Borghi, A, Brambilla, L, Bressan, M, Bruno, A, Caccavale, S, Calogiuri, G, Cannavò, S, Carugno, A, Cataldi, I, Chiarelli, G, Chiesa, A, Cirla, A, Cossutta, M, Cova, L, Cristaudo, A, Dalcan-Ton, M, Damiani, G, Danese, P, Desalvo, V, Fantini, C, Ferrucci, S, Flori, M, Fontana, E, Foti, C, Francalanci, S, Frasin, L, Gola, M, Gravante, M, Guastaferro, D, Ingordo, V, Lauriola, M, Leghissa, P, Lisi, P, Lombardi, P, Lorenzini, M, Magrini, L, Marone, G, Martina, E, Mascagni, P, Matteinichiari, M, Meligeni, L, Melino, M, Milanesi, N, Molinu, A, Monfrecola, G, Morelli, P, Motolese, A, Musumeci, M, Napolitano, M, Nasca, M, Paganini, P, Papini, M, Pasolini, G, Peroni, A, Peserico, A, Piras, V, Pugliese, A, Raponi, F, Raviolo, P, Rebora, A, Recchia, G, Riva, F, Rossi, M, Ruggieri, M, Saggiorato, F, Sartorelli, P, Schena, D, Schettino, A, Spano, G, Stinchi, C, Taddei, L, Tasin, L, Tramontana, M, Valsecchi, R, Vascellaro, A, Venturini, M, Pigatto, Pd, Calzavara-Pinton, P, 'Skin Allergy' group of SIDeMaST and 'SIDAPA' (Agostinelli, D, Arigliano, Pl, Belloni Fortina, A, Cannavò, Sp, Cirla, Am, Cova, Lm, Dal Canton, M, De Salvo, V, Ferrucci, Sm, Flori, Ml, Frasin, La, Lauriola, Mm, Matteini Chiari, M, Molinu, Aa, Musumeci, Ml, Nasca, Mr, Raviolo, Pd, Recchia, Gp, Valsecchi, Rh, Vincenzi, C, Virgili, A, and Zucca, M). more...

Subjects
Dermatitis, contact, Guideline, Patch tests, medicine.medical_specialty, Allergic Contact, Socio-culturale, Dermatitis, Dermatology, Patch tests, Guideline, contact, Patch test, Patch testing, Standard procedure, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Dermatitis, contact, Allergens, Dermatitis, Allergic Contact, Humans, Italy, Patch Tests, medicine, Allergic contact dermatitis, business.industry, Contact dermatitis, medicine.disease, Test (assessment), Family medicine, business
Abstract

Patch testing is the standard procedure used to diagnose allergic contact dermatitis. It is an in-vivo test, which reproduces the reaction to a contact allergen. This in-vivo test aims to reproduce the elicitation phase of allergic contact dermatitis and is performed applying allergens under occlusion on the skin under standardized conditions. These guidelines for the best practice in performing patch test have been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Society of Contact Dermatitis (ESCD) and on the basis of the SIDAPA guidelines. more...

Published
2019

15. Commission Regulation ( EU) No. 412/2012: is dimethyl fumarate still present in products imported from countries outside the European Union?

Author

Milanesi, N., Bartolini, G., Francalanci, S., and Gola, M.

Subjects
*FUMARATES, *MOLD control, *BIOCIDES, *LEATHER, *EQUIPMENT & supplies
Abstract

The article discusses whether dimethyl fumarate (DMF), an effective mould-growth inhibitor, is still present in products imported from countries outside the European Union. It mentions that DMF has wide-spectrum biocide activity and is used to protect leather during storage. It mentions that marketing of DMF in biocidal products has been banned in the European Union since 1998. more...

Published
2017
Full Text
View/download PDF

19. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Hansel, Katharina, Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., and Peris, K. more...

Subjects
Dupilumab Therapy, Antibodies, Monoclonal, Humanized, Disease Progression, Humans, Treatment Outcome, COVID-19, Dermatitis, Atopic, Dermatitis, Atopic dermatitis, Dermatology, Dupilumab, Antibodies, Atopic, Settore MED/35, Monoclonal, Immunology and Allergy, human, Humanized, treatment outcome, Antibodies, Monoclonal, Humanized, COVID-19, Dupilumab Therapy, disease exacerbation, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human, monoclonal antibody, atopic dermatiti
Abstract

N/A

Published
2022

20. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A., Talamonti, M., De Simone, C., Galluzzo, M., Gori, N., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Di Nardo, L., Guarneri, F., Peris, K., Caldarola, G., Silvaggio, D., Dattola, A., Napolitano, M., Ferrucci, S. M., Dal Bello, G., Bianchelli, T., Rovati, C., Pigliacelli, F., Ortoncelli, M., Hansel, K., Calabrese, G., Loi, C., Iannone, M., Veronese, F., Romita, P., Tronconi, G., Caroppo, F., Tilotta, G., Sernicola, A., Esposito, M., Raponi, F., Gualdi, G., Rech, G., Musumeci, M. L., Nistico, S. P., Campitiello, A., Bonzano, L., Piras, V., Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, and Piras, V more...

Subjects
Registrie, 0301 basic medicine, Dermatitis, Systemic therapy, 0302 clinical medicine, Pandemic, Immunology and Allergy, Medicine, Registries, atopic dermatitis, COVID, SARS‐ CoV, treatment, SARS-CoV, Atopic dermatitis, Dupilumab, Italy, Original Article, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human, atopic dermatiti, Adult, medicine.medical_specialty, Teledermatology, SARS‐CoV, atopic dermatitis, treatment, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Communicable Disease Control, Humans, Pandemics, SARS-CoV-2, COVID-19, Dermatitis, Atopic, Atopic, 03 medical and health sciences, Settore MED/35, Disease severity, Internal medicine, business.industry, medicine.disease, 030104 developmental biology, 030228 respiratory system, atopic dermatitis, COVID, SARS-CoV, business
Abstract

Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician‐ and patient‐reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS‐CoV‐2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID‐related death occurred. Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab‐treated patients., Among 1831 studied AD patients, 86.1% were treated with dupilumab. Patients continuing therapy experienced a marked reduction of disease severity during pandemic. The causes of treatment interruption included: fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%), occurrence of comorbidities (5.9%), age above 60 years (5.2%), SARS‐CoV‐2 infection (2.8%), close contact with SARS‐CoV‐2‐positive subject (2.4%), other reasons, for example, inability to maintain drug supply, non‐medical/unspecified causes (58.7%). more...

Published
2021

22. Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab.

Author

Russo F, Cioppa V, Lazzeri L, Milanesi N, Galluzzo M, D'Erme AM, Schettini N, Cocuroccia B, Sordi D, Panebianco A, Talamonti M, Paganini C, De Pità O, Giampetruzzi AR, and Scaglione GL

Abstract

Background and Objective: Atopic Dermatitis (AD) is the most prevalent inflammatory skin disorder resulting in an intense impact on patients quality of life. The aim of this study is to evaluate the clinical meaning of the DLQI scores documented between different phenotypes of AD patients under biologic therapy with Dupilumab. Method: We conducted a retrospective analysis of 209 patients with AD treated with Dupilumab for 2 years. These patients were categorized into different clinical phenotypes. Severity of the disease was assessed by using the Eczema Area and Severity Index (EASI), Numerical Scale Rating (NRS) for sleep (NRS sleep), pruritus (NRS pruritus) and Dermatology Life Quality Index (DLQI) at baseline and subsequently at 4,12 and 24 months. Results: Our results show that the higher DLQI scores (mean: 18.6, range:9-30) achieved at T0 are associated with a prurigo nodularis AD pattern, while after 24 months (T3) of therapy with Dupilumab, the worst quality of life index results were reported in Flexural and Head-Neck combined clinical phenotypes. Conclusions: Quality of life is probably what matters most as an overall endpoint in AD. Assessing the clinical meaning of DLQI scores across different AD phenotypes could be a further aid when considering decision making factors in patient management. more...

Published
2024
Full Text
View/download PDF

23. Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.

Author

Manzo Margiotta F, Michelucci A, Capalbo E, Ricceri F, Rosi E, Rossari S, Magnano M, Savarese I, Milanesi N, Simoni B, Romanelli M, Rubegni P, DI Cesare A, Panduri S, Pescitelli L, Trovato E, and Prignano F more...

Subjects
Humans, Retrospective Studies, Antibodies, Monoclonal therapeutic use, Immunoglobulin Class Switching, Psoriasis drug therapy
Published
2024
Full Text
View/download PDF

24. Dupilumab and Atopic Dermatitis Flares: An Observational Study to Identify Common Clinical Features in Patients Who Have Exacerbations Despite Biological Therapy.

Author

Russo F, Cioppa V, Cartocci A, Milanesi N, D'Erme AM, Lazzeri L, Rubegni P, and Santi F

Subjects
Humans, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal therapeutic use, Biological Therapy, Treatment Outcome, Severity of Illness Index, Dermatitis, Atopic drug therapy
Published
2024
Full Text
View/download PDF

26. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.

Author

Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Gurioli C, Ortoncelli M, Fabbrocini G, Nettis E, Schena D, Napolitano M, Gola M, Bonzano L, Rossi M, Belloni Fortina A, Balato A, Peris K, Foti C, Guarneri F, Romanelli M, Patruno C, Savoia P, Esposito M, Russo F, Errichetti E, Bianchelli T, Bianchi L, Pellacani G, Feliciani C, Offidani A, Corazza M, Micali G, Milanesi N, Malara G, Chiricozzi A, Tramontana M, and Hansel K more...

Subjects
Humans, Adolescent, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal adverse effects, Treatment Outcome, Severity of Illness Index, Double-Blind Method, Dermatitis, Atopic drug therapy
Published
2023
Full Text
View/download PDF

27. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.

Author

Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Ortoncelli M, Fabbrocini G, Nettis E, Schena D, Napolitano M, Gola M, Bonzano L, Rossi M, Belloni Fortina A, Balato A, Peris K, Foti C, Guarneri F, Romanelli M, Patruno C, Savoia P, Fargnoli MC, Russo F, Errichetti E, Bianchelli T, Bianchi L, Pellacani G, Feliciani C, Offidani A, Corazza M, Micali G, Milanesi N, Malara G, Chiricozzi A, Tramontana M, and Hansel K more...

Subjects
Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Pandemics, Prospective Studies, Pruritus, SARS-CoV-2, Severity of Illness Index, Treatment Outcome, Dermatitis, Atopic drug therapy, Eczema, COVID-19 Drug Treatment
Abstract

Background: Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD., Objectives: A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined., Methods: Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes., Results: One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event., Conclusions: Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era., (© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.) more...

Published
2022
Full Text
View/download PDF

28. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy.

Author

Chiricozzi A, Di Nardo L, Talamonti M, Galluzzo M, De Simone C, Fabbrocini G, Marzano AV, Girolomoni G, Offidani A, Rossi MT, Bianchi L, Cristaudo A, Fierro MT, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanesi N, Belloni Fortina A, Bongiorno MR, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese A, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patruno C, Zalaudek I, Lombardo M, Feliciani C, Antonelli F, Ferrucci SM, Guarneri F, and Peris K more...

Subjects
Antibodies, Monoclonal, Humanized therapeutic use, Disease Progression, Humans, Treatment Outcome, COVID-19, Dermatitis, Atopic chemically induced
Abstract

Competing Interests: A.C. served as advisory board member and consultant receiving fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. G.F. acted as speaker and consultant for AbbVie and Leo Pharma. G.G. has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol-Meyers Squibb, Celgene, Eli Lilly, Leo Pharma, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, and Sandoz. A.O. has been a scientific consultant/speaker/clinical study investigator for AbbVie, Celgene, Janssen, Leo Pharma, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, Alfasigma, and Almirall. M.T.R. has received personal fee for advisory board meeting from Sanofi, AbbVie, Novartis, and Cantabria. L.B. reports personal fees from speaker and as consultant for AbbVie, Novartis, Janssen-Cilag, Pfizer, UCB, and Leo Pharma, outside the submitted work. L.S. has been principal investigator in clinical trials sponsored by and/or received personal fees from AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Novartis, and Sanofi-Genzyme. G.P. has been principal investigator in clinical trials sponsored by and/or received personal fees from AbbVie, Almirall, Eli Lilly, Leo Pharma, Novartis, and Sanofi. A.P. has served as a speaker and received honoraria from Sanofi-Genzyme for lectures, research grants, and as an advisory board member. C.F. has been speaker for Sanofi and AbbVie. M.C.F. has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi Genzyme, Roche, Sun Pharma, and MSD. F.R. has served on advisory board, received honoraria for lectures and research grants from Novartis, AbbVie, Janssen-Cilag, Eli Lilly, Leo Pharma, and Sanofi-Genzyme. P.A. has received speaker honoraria from Sanofi, AbbVie, Janssen, Celgene, Novartis, and Sandoz. G.M. has been a scientific consultant/clinical study investigator for AbbVie, Eli Lilly, Janssen-Cilag, Leo Pharma, and Novartis. C.P. has been a consultant and held sponsored conferences for AbbVie, Novartis, Pfizer, and Sanofi. I.Z. has been a consultant and/or speaker for Novartis, Celgene, and Amgen. K.P. reports grants and personal fees for advisory board meeting from Almirall, AbbVie, Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma, and Janssen. S.F. has been principal investigator in clinical trials by AbbVie and Sanofi-Genzyme, has served on advisory board, received honoraria for lectures and research grants from Novartis, Menarini, and Almirall. The remaining authors have no funding or conflicts of interest to declare. more...

Published
2022
Full Text
View/download PDF

29. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis.

Author

Milanesi N, Gola M, Cartocci A, Tronconi G, Bruzziches F, Flori ML, Rubegni P, and Russo F

Subjects
Adult, Antibodies, Monoclonal, Humanized, Female, Humans, Infant, Male, Middle Aged, Pruritus drug therapy, Retrospective Studies, Sleep, Treatment Outcome, Dermatitis, Atopic complications, Sleep Wake Disorders drug therapy
Abstract

Background: Sleep disturbances are common in patients with atopic dermatitis (AD). Considering their relevant burden on health, routine screening of sleep disturbances seems to be very useful in AD adults' management. However, few studies have evaluated the association between sleep disturbances and AD in adults, and real-life data are lacking. The aim of this study was to assess the effect of treatment with dupilumab on sleep disturbances in adult patients with severe atopic dermatitis., Methods: This is a retrospective, multicenter study including patients (age ≥18 y) with severe atopic dermatitis treated with dupilumab for at least 8 months from January 2019 to January 2020. Patients were evaluated three times: at treatment initiation (T0), at 4 (T4) and 8 months (T8) from the start of treatment. At each visit disease activity was assessed by severity score (Eczema Area and Severity Index [EASI]), patient-reported outcomes (Pruritus Numerical Rating Scale [NRS], Dermatology Life Quality Index [DLQI], and Pittsburgh Sleep Quality Index [PSQI]). Kolmogorov-Smirnov Test was performed to evaluate the normality distribution, Bartlett's Test for homoscedasticity. Since the assumptions were met, ANOVA for repeated measures was performed to evaluate the mean difference of PSQI, EASI, DLQI and pruritus NRS between baseline, the 4 th month and the 8 th month. In addition, χ 2 for Trend Test was performed to evaluate the increasing/decreasing prevalence of poor sleepers., Results: A total of 36 patients (15 females and 21 males) with a mean age of 42.5±14.3 (range 20-67) were included in the study. The mean score for PSQI at TO was 9.0±3.6. At week 16 (T4) the mean score for PSQI was 4.92±2.99 and at week 32 (T8), the mean score for PSQI was 4.3±3.0. EASI, NRS pruritus and DLQI significantly improved during follow-up (P<0.001) whereas PSQI improved significantly at 16 weeks (T4); however, no significant further improvement was observed at 32 weeks. Of the 31 patients (86%) with baseline PSQI≥5, 17 (54%) experienced sleep quality improvement during treatment. Overall, we observed a total of 22 patients (61.1%) having a PSQI<5 at 32 weeks., Conclusions: Our data show effectiveness of dupilumab in improving sleep disturbances in adult patients with severe AD. However, further studies are required to understand if PSQI could serve as useful evaluating tool. more...

Published
2022
Full Text
View/download PDF

30. Towards a better understanding of the use of additives in tattoos.

Author

Milanesi N, Gigli U, Tronconi G, Grimaldi G, and Gola M

Subjects
Ink, Tattooing adverse effects
Abstract

Background: Tattooing is a popular practice worldwide, this practice is not free from complications and the last few decades have seen the raising occurrence of complications and adverse reactions., Methods: The aim of this study is to evaluate which substances are commonly used as additives among a group of tattoo artists working in Florence, to understand if mixing of colors and dilution of inks can be considered a potential source of infection or hypersensitivity reaction. A questionnaire containing a list of substances suspected to be added during the process of tattooing, was administered in presence of an investigator., Results: Forty-one licensed tattoo artists participated in the study. The cosmetic most frequently used as additive, resulted a rinse on cosmetic (36%) followed by distilled water (34%) and hamamelis lotion (17%)., Conclusions: Our study provides new insights about the procedure of ink dilution and mixing of colors, shedding light on the possible risks related to the use of non-sterile products. The results of our study suggest that mixing of colors and ink dilution can be consider a potential source of infection and hypersensitivity reactions. Additional actions are necessary to strengthen and protect public health. more...

Published
2022
Full Text
View/download PDF

31. Dupilumab in Elderly Patients With Severe Atopic Dermatitis.

Author

Russo F, Milanesi N, Cartocci A, Bruzziches F, Tronconi G, Lazzeri L, D'erme AM, Bagnoni G, Gola M, Cinotti E, Rubegni P, and Flori ML

Subjects
Adult, Age Factors, Aged, Dermatitis, Atopic diagnosis, Humans, Male, Quality of Life, Retrospective Studies, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Dermatitis, Atopic drug therapy, Severity of Illness Index
Abstract

Background: Atopic dermatitis (AD) in the elderly has been poorly investigated, although its incidence is gradually increasing mainly in industrialized countries. Age-specific factors in older patients must be considered when selecting treatment options., Objectives: To evaluate the efficacy and tolerability of dupilumab in treating elderly patients with severe AD., Methods: This was a retrospective, multicenter study involving 26 elderly patients (age, ≥65 years) with severe AD who were treated with dupilumab for at least 16 weeks. Absolute and percentage frequencies were used to evaluate qualitative variables and mean and SD for quantitative ones. For Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale (NRS), and Dermatology Life Quality Index (DLQI), the median was also calculated. Wilcoxon test was used to evaluate the variations in EASI, Pruritus NRS, and DLQI observed between the 2 examinations., Results: After 4 months of therapy, the majority of patients showed a significant improvement in EASI (64.4%), Pruritus NRS (58.2%), and DLQI (44.9%). Only 11% of patients reported mild or moderate conjunctivitis., Conclusions: To the best of our knowledge, this is the first study concerning the use of dupilumab in the elderly with severe AD. Our data show the effectiveness of dupilumab in this particular population with a lower percentage of conjunctivitis than observed in studies on adults and also excellent control of itching. Only larger, controlled case studies will be able to clarify whether the dosage or frequency of administration of dupilumab in these patients should be different from the protocol used for adults., Competing Interests: The authors have no funding or conflicts of interest to declare., (Copyright © 2020 American Contact Dermatitis Society. All Rights Reserved.) more...

Published
2021
Full Text
View/download PDF

32. Myroxylon pereirae (balsam of Peru): Still worth testing?

Author

Guarneri F, Corazza M, Stingeni L, Patruno C, Napolitano M, Pigatto PDM, Gallo R, Cristaudo A, Romita P, Offidani A, Schena D, Milanesi N, Micali G, Zucca M, and Foti C

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Balsams adverse effects, Dermatitis, Allergic Contact etiology, Female, Hexoses administration & dosage, Hexoses adverse effects, Humans, Male, Middle Aged, Odorants, Retrospective Studies, Young Adult, Balsams administration & dosage, Dermatitis, Allergic Contact diagnosis, Patch Tests methods
Abstract

Background: Because Myroxylon pereirae (MP), or balsam of Peru, is nowadays almost not used "as such," and fragrance mix 1 (FM1) apparently is more sensitive in detecting fragrance allergy, the usefulness of testing MP in baseline series was recently questioned., Objectives: Identification of the number of clinically relevant patch test reactions to MP not detected by FM1., Methods: Retrospective analysis of 12 030 patients patch tested with MP and FM1 for contact dermatitis between January 2018 and December 2019 in 13 Italian dermatology clinics., Results: Four hundred thirty-nine patients (3.6%) had a positive patch test reaction to MP; 437 (3.6%) had a positive patch test reaction to FM1. Positive reactions to both MP and FM1 were observed in 119 subjects (1.0%), 310 (2.6%) reacted to MP only, 304 (2.5%) to FM1 only, 5 to MP and sorbitan sesquioleate (SSO), 9 to FM1 and SSO, and 5 to MP, FM1, and SSO. Single sensitizations were clinically relevant in 75.2% of cases for MP (62.9% current, 12.3% past) and 76.3% for FM1 (70.1% current, 6.2% past)., Conclusions: Based on our results, MP appears to be still worth testing along with FM1 in baseline series, because it allows detection of a remarkable number of fragrance allergies, often relevant, which would be otherwise missed., (© 2021 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.) more...

Published
2021
Full Text
View/download PDF

33. Patch testing of budesonide in Italy: The SIDAPA baseline series experience, 2018-2019.

Author

Stingeni L, Marietti R, Bianchi L, Guarneri F, Ferrucci SM, Faraci AG, Foti C, Romita P, Patruno C, Napolitano M, Gallo R, Corazza M, Schena D, Milanesi N, Bruni F, Pigatto P, Musumeci ML, Martina E, Piras V, Tramontana M, and Hansel K more...

Subjects
Adult, Age Distribution, Aged, Budesonide immunology, Cross Reactions, Dermatitis, Atopic diagnosis, Dermatitis, Atopic epidemiology, Dermatitis, Occupational diagnosis, Dermatitis, Occupational epidemiology, Female, Humans, Italy epidemiology, Male, Middle Aged, Prevalence, Retrospective Studies, Sex Distribution, Budesonide adverse effects, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact epidemiology, Patch Tests methods
Abstract

Background: Budesonide was included in the European Baseline Series in 2000 as the most suitable marker forcorticosteroid hypersensitivity. In the last two decades, a decreasing trend of budesonide allergy has been observed., Objectives: To estimate the prevalence of positive patch test reactions to budesonide in a large, Italian patch test population, characterizing patients according to MOAHLFA index and evaluating the benefit with extended readings of budesonide patch test., Methods: Retrospective analysis of patient demographics and patch test results over a 2-year period (2018-2019) was performed at 14 patch test clinics in Italy., Results: Ninety out of 14 544 (0.6%) patients reacted to budesonide 0.01% pet.. Positive reactions were mild in 54.4% and late readings at day 7 showed new positive reactions in 37.8% of patients. The MOAHLFA index showed a significant positive association with male gender, atopic dermatitis, and age >40 years and a significant negative association with hand and face dermatitis., Conclusions: We documented a low prevalence of budesonide allergy in Italy, confirming its decreasing trend recently reported in the literature. Nevertheless, budesonide needs to be maintained in the baseline series for its good ability to detect corticosteroid sensitization., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.) more...

Published
2021
Full Text
View/download PDF

34. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.

Author

Chiricozzi A, Talamonti M, De Simone C, Galluzzo M, Gori N, Fabbrocini G, Marzano AV, Girolomoni G, Offidani A, Rossi MT, Bianchi L, Cristaudo A, Fierro MT, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanesi N, Belloni Fortina A, Bongiorno MR, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese A, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patruno C, Zalaudek I, Lombardo M, Feliciani C, Di Nardo L, Guarneri F, and Peris K more...

Subjects
Adult, Communicable Disease Control, Humans, Italy epidemiology, Pandemics, Registries, SARS-CoV-2, COVID-19, Dermatitis, Atopic drug therapy, Dermatitis, Atopic epidemiology
Abstract

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic., Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity., Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred., Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients., (© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.) more...

Published
2021
Full Text
View/download PDF

36. Evaluation of nine patients with solar urticaria during summer.

Author

Milanesi N, Gola M, and Francalanci S

Subjects
Adult, Combined Modality Therapy, Dermatologic Agents therapeutic use, Female, Humans, Interpersonal Relations, Male, Middle Aged, Photosensitivity Disorders epidemiology, Photosensitivity Disorders therapy, Seasons, Ultraviolet Therapy, Urticaria epidemiology, Urticaria therapy, Young Adult, Anxiety etiology, Depression etiology, Photosensitivity Disorders psychology, Urticaria psychology
Published
2020
Full Text
View/download PDF

37. Severe Adult Atopic Dermatitis: Clinical Challenges.

Author

Russo F, Flori ML, Gola M, and Milanesi N

Subjects
Adult, Antibodies, Monoclonal, Humanized immunology, Dermatitis, Atopic immunology, Dermatologic Agents immunology, Humans, Severity of Illness Index, Antibodies, Monoclonal, Humanized therapeutic use, Dermatitis, Atopic diagnosis, Dermatitis, Atopic drug therapy, Dermatologic Agents therapeutic use
Published
2020
Full Text
View/download PDF

38. Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitis.

Author

Russo F, Milanesi N, Iannone M, Bagnoni G, Bartoli L, Bellini M, Brandini L, Buggiani G, Cecchi R, Cuccia A, D'erme AM, Dini V, Gori A, Grazzini M, Marsili F, Masci G, Mazzoli S, Peccianti C, Pellegrino M, Pimpinelli N, Rubegni P, Taviti F, Tedeschi C, Tonini G, Mazzatenta C, Flori ML, and Gola M more...

Subjects
Adult, Dermatitis, Atopic diagnosis, Dermatitis, Atopic pathology, Humans, Severity of Illness Index, Dermatitis, Atopic therapy, Interdisciplinary Communication
Abstract

Atopic dermatitis (AD) is an inflammatory disease with a chronic-relapsing course that is intensely itchy. A correct diagnosis of AD in adults and consequently appropriate clinical therapeutic management is a critical issue for extreme clinical expression heterogeneity and various grades of disease severity. In order to ensure high levels of care and standardization of clinical therapeutic management of Adult AD, the decision was taken to create an AD Tuscan Consensus Group (the Group), to work on and validate a consensus based regional clinical-therapeutic management model. The aims of the Group were to find agreement on the criteria for diagnosis, scoring of severity, multidisciplinary approach and treatment of adult atopic dermatitis and to create an easier way for patients to access specialized dermatology outpatient services and importantly to reduce waiting lists and costs related to the management of AD. The Tuscan Consensus Group adopted a simplified Delphi method, in three principal steps: 1) literature metanalysis and critical review of patient's clinical experience to identify the main areas considered questionable or uncertain; 2) discussion of those areas requiring consensus and statement definition through four different sub-committees (diagnosis, severity evaluation, scoring and comorbidities); 3) a consensus based simplified process with final approval of each statement by plenary vote with approval >80% of the participants. The Group here presents and discusses the consensus based recommendation statements on adult atopic dermatitis. more...

Published
2020
Full Text
View/download PDF

39. Contact allergy to 3-dimethylaminopropylamine in 5140 consecutive Italian patients: A one-year retrospective multicenter SIDAPA study.

Author

Foti C, Romita P, Cristaudo A, Corazza M, Gallo R, Massari F, Milanesi N, Napolitano M, Nettis E, Patruno C, Pigatto PD, Schena D, Hansel K, Stingeni L, and Guarneri F

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Dermatitis, Allergic Contact epidemiology, Female, Humans, Italy epidemiology, Male, Middle Aged, Patch Tests, Retrospective Studies, Dermatitis, Allergic Contact etiology, Diamines adverse effects
Published
2020
Full Text
View/download PDF

40. Patch test with sorbitan sesquioleate in Italian consecutive patients: A 1-year multicenter SIDAPA study.

Author

Stingeni L, Tramontana M, Bianchi L, Foti C, Romita P, Patruno C, Cristaudo A, Gallo R, Corazza M, Schena D, Pigatto PD, Milanesi N, Nettis E, Guarneri F, and Hansel K

Subjects
Female, Humans, Italy, Male, Middle Aged, Patch Tests methods, Allergens adverse effects, Dermatitis, Allergic Contact etiology, Hexoses adverse effects, Surface-Active Agents adverse effects
Published
2019
Full Text
View/download PDF

41. Efficacy and safety of S-acyl glutathione 2% cream vs. placebo against UVB-induced erythema: a randomized, double-blinded clinical trial.

Author

Grandi V, Milanesi N, Sessa M, Gola M, Cappugi P, and Pimpinelli N

Subjects
Acetylation, Adult, Antioxidants chemistry, Antioxidants pharmacology, Cross-Sectional Studies, Double-Blind Method, Erythema etiology, Female, Glutathione chemistry, Glutathione pharmacology, Humans, Male, Middle Aged, Reactive Oxygen Species metabolism, Skin Cream, Antioxidants administration & dosage, Erythema prevention & control, Glutathione administration & dosage, Ultraviolet Rays adverse effects
Abstract

Background: Reactive oxygen species have a major role in the UV-induced short- and long-term damage, thus the exogenous supplementation of antioxidant molecules may allow better skin protection. Despite glutathione has pivotal properties in the complex cytoplasmic antioxidant system, its supplementation is hampered by limited transmembrane absorption. Modification of glutathione pharmacokinetic properties via acetylation with long-chain polyunsaturated fatty acid may improve its passage through phospholipidic membranes., Methods: This was a single center randomized double-blinded clinical trial, versus placebo, cross-sectional pairwise at time 0. The participants were 10 healthy volunteers with skin phototypes II or III and age ≥18 years interested in performing minimal erythema dose (MED) evaluation performed by photoallergology unit of Division of Dermatology at P. Palagi Hospital, in Florence. Each volunteer underwent UVB phototesting, treating four different areas with increasing UVB doses in four different conditions. One arm was treated as standard procedure (naïve arm), one applying linolenic-glutathione conjugate (Lin-GSH) cream 2% before irradiation (pre-Lin-GSH arm), one with placebo (placebo arm) and one applying Lin-GSH cream 2% (SoloSale Srl, Florence, Italy) after irradiation (post-Lin-GSH arm). The main endpoint was to evaluate efficacy of Lin-GSH cream 2% before UVB irradiation compared with placebo. A secondary endpoint was the evaluation of the same cream applied after irradiation compared to no treatment. Another secondary objective is the evaluation of safety in both conditions. Mean MED was evaluated at distinct conditions. Safety was evaluated reporting all grade 3-4 adverse events up to 30 days after treatment. All volunteers were treated in all four experimental conditions. The pre-Lin-GSH and placebo arms were applied in a double-blind condition for each volunteer. Neither the volunteer nor the investigator executing MED evaluation knew which arm was given Lin-GSH and which one placebo., Results: Ten volunteers among 12 recruited for the study were correctly randomized and completed all study evaluations. Recruitment went from April 1st, 2016 to May 1st, 2016, up to adequate population number. Mean MED in pre-Lin-GSH arm was superior to mean MED in placebo arm (135±5.53 mJ/cm2 vs. 105±7.64 mJ/cm2, P=0.0003). No difference was observed among mean MED in post-Lin-GSH and naïve arms. No grade 3-4 adverse events were reported., Conclusions: Lin-GSH 2% cream seems a safe and effective in producing a significant increase in MED compared with placebo thanks to its antioxidant properties. more...

Published
2019
Full Text
View/download PDF

42. Contact sensitivity to 2-hydroxyethyl methacrylate in consecutive patients: A 1-year multicentre SIDAPA study.

Author

Stingeni L, Tramontana M, Bianchi L, Foti C, Patruno C, Gallo R, Corazza M, Schena D, Milanesi N, Guarneri F, Bini V, and Hansel K

Subjects
Acrylates adverse effects, Adult, Female, Humans, Male, Methylmethacrylate adverse effects, Middle Aged, Patch Tests methods, Polyethylene Glycols adverse effects, Polymethacrylic Acids adverse effects, Dermatitis, Allergic Contact etiology, Methacrylates adverse effects
Published
2019
Full Text
View/download PDF

43. Photosensitivity in drug induced pellagra.

Author

Milanesi N, Gola M, and Francalanci S

Subjects
Adolescent, Azathioprine administration & dosage, Colitis, Ulcerative drug therapy, Drug Eruptions diagnosis, Drug Eruptions etiology, Female, Humans, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents adverse effects, Azathioprine adverse effects, Pellagra chemically induced, Photosensitivity Disorders etiology
Published
2019
Full Text
View/download PDF

44. Allergic contact dermatitis caused by a polyurethane catheter.

Author

Milanesi N, Gola M, and Francalanci S

Subjects
Administration, Intravenous, Adult, Anti-Bacterial Agents administration & dosage, Cystic Fibrosis drug therapy, Humans, Male, Patch Tests, Catheterization, Peripheral instrumentation, Central Venous Catheters adverse effects, Dermatitis, Allergic Contact etiology, Polyurethanes adverse effects
Published
2018
Full Text
View/download PDF

46. Allergic contact dermatitis caused by VEA(®) lipogel: compound allergy?

Author

Milanesi N, Gola M, and Francalanci S

Subjects
Adolescent, Adult, Antioxidants adverse effects, Child, Dermatitis, Atopic drug therapy, Dermatologic Agents chemistry, Female, Humans, Lichen Sclerosus et Atrophicus drug therapy, Male, Middle Aged, Patch Tests, Young Adult, alpha-Tocopherol adverse effects, Cosmetics adverse effects, Dermatitis, Allergic Contact etiology, Dermatologic Agents adverse effects
Published
2016
Full Text
View/download PDF

47. Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone.

Author

D'Erme AM, Boca A, Sabau M, Milanesi N, Simonacci F, and Gola M

Subjects
Acute Disease, Administration, Oral, Administration, Topical, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Facial Dermatoses diagnosis, Facial Dermatoses drug therapy, Female, Follow-Up Studies, Humans, Macrolides therapeutic use, Middle Aged, Severity of Illness Index, Treatment Outcome, Clarithromycin therapeutic use, Prednisone therapeutic use, Rosacea diagnosis, Rosacea drug therapy
Published
2016
Full Text
View/download PDF

48. Irritant contact dermatitis caused by Savoy cabbage.

Author

Milanesi N and Gola M

Subjects
Arthralgia therapy, Humans, Isothiocyanates adverse effects, Male, Middle Aged, Occlusive Dressings, Brassica adverse effects, Dermatitis, Irritant etiology, Medicine, Traditional adverse effects, Self Medication adverse effects
Published
2016
Full Text
View/download PDF

49. The Utility of Patch Testing Methylisothiazolinone 2000 ppm aqua.

Author

Milanesi N, Gola M, and Francalanci S

Subjects
Adolescent, Adult, Aged, Child, Dermatitis, Allergic Contact etiology, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Young Adult, Dermatitis, Allergic Contact diagnosis, Patch Tests methods, Thiazoles adverse effects
Published
2015
Full Text
View/download PDF

50. Gluten-free diet as a therapeutic approach in psoriatic patients: if yes, when.

Author

D'Erme AM, Kovacikova Curkova A, Agnoletti AF, Milanesi N, Simonacci F, and Gola M

Subjects
Autoantibodies blood, Autoantibodies immunology, Autoantigens immunology, CD4-Positive T-Lymphocytes immunology, Celiac Disease diagnosis, Celiac Disease epidemiology, Comorbidity, Disease Management, Disease Susceptibility, GTP-Binding Proteins immunology, Gliadin adverse effects, Gliadin immunology, Humans, Models, Immunological, Prospective Studies, Protein Glutamine gamma Glutamyltransferase 2, Psoriasis epidemiology, Psoriasis etiology, Psoriasis immunology, Time Factors, Transglutaminases immunology, Treatment Outcome, Vitamin D Deficiency epidemiology, Celiac Disease diet therapy, Diet, Gluten-Free, Psoriasis diet therapy
Abstract

Since most of the studies are mainly confined to cases reporting coincidence of psoriasis and celiac disease, the authors want to underline the utility of investigating the possible presence of an underlying celiac disease in normal practice for a better approach to the patient. It is necessary to carry out controlled studies on a large number of patients to evaluate the association between these two diseases and the benefits of a gluten-free diet, even when the intestinal symptomatology is not evident. more...

Published
2015